
Hamim Zahir

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3593351/publications.pdf Version: 2024-02-01



| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors. Journal of Clinical Pharmacology, 2021, 61, 480-492. | 1.0 | 8 |
| 2 | Evaluation of Potential Drugâ€Ðrug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and Pâ€Glycoprotein. Journal of Clinical Pharmacology, 2021, 61, 298-306. | 1.0 | 8 |
| 3 | Exposure–response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1422-1432. | 1.3 | 7 |
| 4 | Abuse potential of mirogabalin in recreational polydrug users. Therapeutic Advances in Drug Safety, 2019, 10, 204209861983603. | 1.0 | 8 |
| 5 | Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours. British Journal of Clinical Pharmacology, 2018, 84, 112-121. | 1.1 | 8 |
| 6 | Open-Label Single-Dose Study to Assess the Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics of Mirogabalin. Clinical Drug Investigation, 2018, 38, 1001-1009. | 1.1 | 10 |
| 7 | Coadministration of probenecid and cimetidine with mirogabalin in healthy subjects: A phase 1, randomized, open″abel, drug–drug interaction study. British Journal of Clinical Pharmacology, 2018, 84, 2317-2324. | 1.1 | 13 |
| 8 | Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: Results from phase 1 studies. Pharmacology Research and Perspectives, 2018, 6, e00418. | 1.1 | 20 |
| 9 | Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Mirogabalin When Coadministered With Lorazepam, Zolpidem, Tramadol, or Ethanol: Results From Drugâ€Drug Interaction Studies in Healthy Subjects. Clinical Pharmacology in Drug Development, 2018, 7, 597-612. | 0.8 | 8 |
| 10 | Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal. Critical Care, 2016, 20, 273. | 2.5 | 19 |
| 11 | Edoxaban Effects on Bleeding Following Punch Biopsy and Reversal by a 4-Factor Prothrombin Complex Concentrate. Circulation, 2015, 131, 82-90. | 1.6 | 240 |
| 12 | Metabolism and disposition of [¹⁴ C]tivantinib after oral administration to humans, dogs and rats. Xenobiotica, 2014, 44, 996-1008. | 0.5 | 11 |
| 13 | Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor. American Journal of Cardiovascular Drugs, 2013, 13, 331-342. | 1.0 | 179 |
| 14 | Edoxaban administration following enoxaparin: A pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects. Thrombosis and Haemostasis, 2012, 108, 166-175. | 1.8 | 36 |